Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today shared more data on the ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Even without the contribution from GLP-1 drugs, revenue growth would have soared. The stock is cheap given the company's revenue growth and margins. Hims & Hers strong performance involves much ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...